Corvus Pharmaceuticals (CRVS) Current Assets (2015 - 2026)

Corvus Pharmaceuticals' Current Assets history runs 12 years deep, the most recent figure standing at $239.9 million for Q1 2026.

• In Q1 2026, Current Assets rose 427.46% year-over-year to $239.9 million; the TTM figure through Mar 2026 stood at $239.9 million (up 427.46% YoY), while the FY2025 annual figure was $58.2 million, up 7.0% from the prior year.
• Current Assets was $239.9 million for Q1 2026 at Corvus Pharmaceuticals, up from $58.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $239.9 million in Q1 2026 to a low of $22.9 million in Q1 2024.
• Historically, Current Assets has averaged $59.3 million across 5 years, with a median of $48.3 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Current Assets slumped 44.77% in 2023, then surged 427.46% in 2026.
• A 5-year view of Current Assets shows it stood at $43.7 million in 2022, then slumped by 35.97% to $28.0 million in 2023, then soared by 94.62% to $54.4 million in 2024, then grew by 7.0% to $58.2 million in 2025, then jumped by 312.18% to $239.9 million in 2026.
• The last three Current Assets figures came in at $239.9 million (Q1 2026), $58.2 million (Q4 2025), and $66.9 million (Q3 2025), per Business Quant data.